AstraZeneca Reports Four-Year CASPIAN Data for Imfinzi in Small Cell Lung Cancer

AstraZeneca today presented four-year overall survival data from the Phase 3 CASPIAN trial evaluating Imfinzi (durvalumab) plus platinum-based chemotherapy in patients with extensive-stage small cell lung cancer. The data showed that the overall survival benefit of Imfinzi was maintained at four years, with 18% of patients in the Imfinzi arm alive at four years compared to 12% in the chemotherapy arm.